Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brexit: Bids In For The EMA As Portugal Drops Lisbon For Porto, Bratislava Emerges As Possible Front-Runner

Executive Summary

All bids to host the European Medicines Agency were to have been in by close of business on July 31. Portugal has unexpectedly switched its candidacy from Lisbon to Porto, Bratislava could emerge as a surprise favorite. Meanwhile the CEO of AstraZeneca has said investment decisions are being put on hold pending more clarity over Brexit.

You may also be interested in...



19 Countries Have Submitted Bids To Host The EMA Post-Brexit

Formal offers to host the European Medicines Agency were received from 19 countries by the deadline of July 31. The European Commission will now begin assessing the bids on the basis of six criteria, with a final decision expected in November.

Pharma Execs Urge Post-Brexit Regulatory Deal, As EMA Focuses On Redistribution Of MHRA Work

Spurred by an apparent shift towards a more pro-business stance among government ministers, a number of top pharmaceutical executives and heads of UK industry bodies have publicly called for some form of regulatory alignment deal between the UK and the EU after Brexit.

EU Postpones Decision On EMA’s New Home To November

The decision on where the European Medicines Agency should be located after the UK leaves the EU has been postponed to November. The European Council has published details of the bidding process countries must follow if they want to host the EMA.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS121218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel